Canaccord Genuity reaffirmed their buy rating on shares of Heska (NASDAQ:HSKA) in a research report sent to investors on Friday, Marketbeat.com reports. Canaccord Genuity currently has a $115.00 price target on the medical research company’s stock, up from their previous price target of $100.00.
Several other research analysts also recently weighed in on HSKA. BidaskClub downgraded shares of Heska from a sell rating to a strong sell rating in a research report on Wednesday, January 31st. ValuEngine downgraded shares of Heska from a hold rating to a sell rating in a research report on Friday, February 2nd. Sidoti upgraded shares of Heska from a neutral rating to a buy rating and set a $94.00 price target on the stock in a research report on Monday, February 5th. B. Riley set a $93.00 price target on shares of Heska and gave the stock a hold rating in a research report on Monday, February 26th. Finally, TheStreet downgraded shares of Heska from a b- rating to a c+ rating in a research report on Friday, March 9th. Three research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of Buy and a consensus price target of $106.75.
Shares of HSKA stock opened at $102.20 on Friday. Heska has a 12-month low of $56.59 and a 12-month high of $115.00. The company has a market capitalization of $762.29 million, a P/E ratio of 58.40 and a beta of 0.68.
Heska (NASDAQ:HSKA) last released its quarterly earnings results on Friday, May 4th. The medical research company reported $0.28 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.40 by ($0.12). Heska had a return on equity of 13.30% and a net margin of 5.57%. The business had revenue of $32.77 million during the quarter, compared to the consensus estimate of $31.65 million. analysts expect that Heska will post 1.98 EPS for the current fiscal year.
Hedge funds have recently made changes to their positions in the company. Quantitative Systematic Strategies LLC bought a new stake in shares of Heska during the 4th quarter valued at $206,000. Landscape Capital Management L.L.C. bought a new stake in shares of Heska during the 4th quarter valued at $209,000. Envestnet Asset Management Inc. raised its position in shares of Heska by 85.8% during the 1st quarter. Envestnet Asset Management Inc. now owns 2,755 shares of the medical research company’s stock valued at $218,000 after purchasing an additional 1,272 shares during the period. MetLife Investment Advisors LLC bought a new stake in shares of Heska during the 4th quarter valued at $263,000. Finally, Virginia Retirement Systems ET AL bought a new stake in shares of Heska during the 1st quarter valued at $411,000. Hedge funds and other institutional investors own 88.16% of the company’s stock.
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.